期刊文献+

HPLC法测定左乙拉西坦含量及其有关物质 被引量:3

Determination of the content and related substances of levetiracetam by HPLC
下载PDF
导出
摘要 建立HPLC法测定左乙拉西坦含量及其有关物质。选用Agilent-Zorbax SIL柱(5μm,4.6 mm×250 mm);流动相为V(乙腈)∶V(1.96 g/L硫酸水)=97.5∶2.5;流速1.0 mL/min;检测波长205 nm;柱温45℃。左乙拉西坦在40.00~240.00μg/mL浓度内线性关系良好,杂质A检测限为0.04 ng,杂质B检测限为0.096 ng,回收率99.5%~101.3%,RSD0.16%~0.57%。本试验建立的左乙拉西坦含量及其有关物质测定方法专属性强、准确度高,具有较高的灵敏度,可用于其质量控制。 An HPLC method for the determination of the content and the related substances of levetiracetam was established.An Agilent-Zorbax SIL column(5 μm,4.6 mm× 250 mm) for levetiracetam determination was used with the mobile phase of acetonitrile 1.96 g/L solution of sulfuric acid(97.5∶2.5 V/V).The flow rate was 1.0 mL/min.The detection wavelength was 205 nm,and the colunm temperature was at 45 ℃.The calibration curve of levetiracetam content was linear in the concentration range of 40.00~240.00 μg/mL.The LOQ of impurity A was 0.04 ng,the LOD of impurity B was 0.096 ng,and the average recoveries were 99.5%~101.3% with RSDs of 0.16%~0.57%.The method is specific,accurate,high sensitivity,and can be used for quality control of levetiracetam drug substance.
出处 《化学试剂》 CAS CSCD 北大核心 2013年第4期337-340,368,共5页 Chemical Reagents
关键词 左乙拉西坦 高效液相色谱法 含量 有关物质 levetiracetam HPLC content related substances
  • 相关文献

参考文献9

  • 1刘腾,赵志刚.左乙拉西坦的药理和临床评价[J].中国新药杂志,2007,16(9):733-735. 被引量:17
  • 2ZUFIA L, ALDAZ A, IBANEZ N, et al. LC method for therapeutic drug monitoring of levetiracetam : evaluation of the assay performance and validation of its application in the routine area [ J ]. Clin. Biochem. , 2010,43 ( 4/5 ) : 473 -482.
  • 3丁庆明,任连坤.抗癫痫新药左乙拉西坦的临床应用和安全性[J].药物不良反应杂志,2007,9(4):295-301. 被引量:40
  • 4ZHOU Jun-ying,TANG Xiang-dong, HUANG Li-li, et al. The acute effects of levetiracetam on nocturnal sleep and daytime sleepiness in patients with partial epilepsy [ J ]. J. Clin. Neurosci. , 2012,19 ( 7 ) : 956-960.
  • 5ISOHERRANEN N, ROEDER M, SOBACK S, et al. Enantioselective analysis of levetiracetam and its enantiomer R-α-ethyl-2-oxo-pyrrolidine acetamide using gas chromatography and ion trap mass spectrometric detection [ J ]. J. Chromatogr. B : Biomed. Sci. Appl. , 2000,745 ( 2 ) : 325-332.
  • 6CONTIN M,MOHAMED S,ALBANI F,et al. Simple and validated HPLC-UV analysis of levetiracetam in deproteinized plasma of patients with epilepsy [ J ]. J. Chromatogr. B,2008,873( 1 ) : 129-132.
  • 7VERMEIJ T A C, EDELBROEK P M. High-performance liquid chromatographic and megabore gas-liquid chromatographic determination of levetiraetam ( ucb L059) in human serum after solid-phase extraction [ J ]. J. Chromatogr. B, Biomed. Sci. Appl. , 1994,662 ( 1 ) : 134-139.
  • 8SHIHABI Z K, OLES K, HINSDALE M. Analysis of the antiepileptic drug keppra by capillary electrophoresis [J]. J. Chromatogr. A ,2003,1 004(1/2) :9-12.
  • 9RAO B M,RAVI R, REDDY B S S, et al. A validated chiral LC method for the enantioselective analysis of levetiracetam and its enantiomer R-α-ethyl-2-oxo-pyrrolidine acetamide on amylase-based stationary phase [ J ]. J. Pharm. Biomed. Anal. ,2004,35(5) :1017-1026.

二级参考文献51

  • 1吴洵昳,洪震,吴逊,吴立文,赵忠新,王学峰,周东,吕传真.多中心双盲、随机、安慰剂对照评价左乙拉西坦添加治疗难治性部分性癫癎发作的疗效及安全性[J].中华神经科杂志,2007,40(3):149-153. 被引量:44
  • 2NIESPODZIANY I, KLITGAARD H, MARGINEANU DG. Levetiracetam : modulation of high voltage activated Ca^2 + current in Cal pyramidal neurons of rat hippocampal slices [ J ]. Epilepsia, 2000,41 ( Suppl 7 ) :S37.
  • 3NIESPODZIANY I, KLITGAARD H, MARGINEANU DG. Levetiracetam inhibits the high-voltage-activated Ca^2 + current in pyramidal neurones of rat hippoeampal slices[ J]. Neurosci Lett, 2001 , 306 ( 1/2 ) :5 - 8.
  • 4LUKYANETZ EA, SHKRYL VM, KOSTYUK PG .Selective blockade of N-type calcium channels by levetiracetam [ J ]. Epilepsia, 2002,43( 1 ) :9 - 18.
  • 5SIRVEN Jl. Neurocysticercosis: nursing perspectives[ J]. J Neurosci Nurs, 2002,34( 5 ) :237 - 241.
  • 6GLAUSER TA, PELLOCK JM, BEBIN EM,et al. Efficacy and safety of levetiracetam in children with partial seizures: an openlabel trial [ J ]. Epilepsia, 2002,43 ( 5 ) :518 - 524.
  • 7GLAUSER TA,AYALA R,ELTERMAN RD,et al. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures [ J ]. Neurology,2006,66( 11 ) : 1654 - 1660.
  • 8PRIVITERA M. Efficacy of levetiracetam: a review of three pivotal clinical trials [ J ]. Epilepsia, 2001,42 ( Suppl 4 ) :S31 - S35.
  • 9BEN-MENACHEM E, EDRICH P, VAN VLEYMEN B,et al. Evidence for sustained efficacy of levetiracetam as add-on epilepsy therapy [ J ]. Epilepsy Res, 2003,53 ( 1/2 ) :57 - 64.
  • 10BEN-MENACHEM E, FALTER U. Efficacy and tolerability of levetiracetam 3 000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy European Levetiraeetam Study Group[J]. Epilepsia,2000,41 (10) : 1276 - 1283.

共引文献53

同被引文献35

  • 1崔蕊,李文莉,崔超,张丹.HPLC测定左乙拉西坦中的右旋异构体[J].华西药学杂志,2010,25(5):593-594. 被引量:2
  • 2田国红,赵忠新.左乙拉西坦——一种具有全新作用机制的抗癫痫新药[J].中国新药与临床杂志,2006,25(10):782-786. 被引量:43
  • 3丁庆明,任连坤.抗癫痫新药左乙拉西坦的临床应用和安全性[J].药物不良反应杂志,2007,9(4):295-301. 被引量:40
  • 4US Pharmacopeia Convention. USP36/NF31 [ S ]. Bahimore, MD: United Book Press,2013:4084-4086.
  • 5Council of Europe. EPS. 0 [ S ]. Beck Nordlingen : Druckerei C. H,2013:2352 - 2353.
  • 6British Pharmacopoeia Commission. Bit2014 [ S ]. London: The stationery Office,2010:2313 - 2316.
  • 7Zhou Junying, Tang Xiangdong, Huang Lili, et al. The acute effects of levetiracetarn on nocturnal sleep and daytime sleepiness in patients with partial epilepsy [ J ]. J Clin Neurosci ,2012,19(7): 956-960.
  • 8Armel S, Sarah L, Fransoise T. Clinical pharmacology of levetiracetam for the treatment of epilepsy [J ]. Expert Rev Pharmacol, 2009,2(4): 339-350.
  • 9US Pharmacopeia Convention. USP 36/NF31 [ M ]. Baltimore, M D: United Book Press, 2013:4 084-4 086.
  • 10Council of Europe. EP8.0 [ M ]. Beck Nordlingen: Druckerei C H, 2013:2 352-2 353.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部